Proteasome Inhibitor
Showing 1 - 25 of 7,614
Kidney Transplantation, End Stage Kidney Disease (ESRD) Trial in Chicago (Belatacept Injection)
Recruiting
- Kidney Transplantation
- End Stage Kidney Disease (ESRD)
- Belatacept Injection
-
Chicago, IllinoisUniversity of Chicago
May 13, 2022
Multiple Myeloma Trial (Elranatamab (PF-06863135))
Temporarily not available
- Multiple Myeloma
- Elranatamab (PF-06863135)
- (no location specified)
Jul 15, 2022
Based on Maintenance Therapy Post Autologous Stem Cell
Recruiting
- Multiple Myeloma
- Autologous Stem Cell Transplant
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Jul 27, 2022
Relapsed and/or Refractory Multiple Myeloma Trial in Japan (Ixazomib, Bortezomib, Carfilzomib)
Completed
- Relapsed and/or Refractory Multiple Myeloma
- Ixazomib
- +4 more
-
Kamogawa, Chiba, Japan
- +22 more
Jul 27, 2022
MMRR Treated With Belantamab Mafotidine on Monotherapy
Not yet recruiting
- Multiple Myeloma
- Belantamab mafodotin
- (no location specified)
May 23, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta, Ann Arbor, Saint Louis (Dexamethasone, Ixazomib,
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +2 more
-
Atlanta, Georgia
- +3 more
Jan 6, 2023
Multiple Myeloma Trial in Beijing, Jiang Su Province (Belantamab mafodotin)
Completed
- Multiple Myeloma
- Belantamab mafodotin
-
Beijing, China
- +2 more
Feb 8, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 3, 2022
Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma Trial in United States (ixazomib citrate, dexamethasone,
Active, not recruiting
- Refractory Plasma Cell Myeloma
- Recurrent Plasma Cell Myeloma
- ixazomib citrate
- +2 more
-
Scottsdale, Arizona
- +4 more
Mar 28, 2022
Multiple Myeloma in Relapse Trial in Finland, Sweden (Carfilzomib for Inj 60 milligram (MG), Elotuzumab 400 MG, Dexamethasone)
Active, not recruiting
- Multiple Myeloma in Relapse
- Carfilzomib for Inj 60 milligram (MG)
- +2 more
-
Helsinki, Finland
- +7 more
Mar 14, 2022
Plasma Cell Myeloma, Residual Disease Trial in Chicago (Ixazomib Citrate, Lenalidomide, Dexamethasone)
Active, not recruiting
- Plasma Cell Myeloma
- Residual Disease
- Ixazomib Citrate
- +2 more
-
Chicago, IllinoisUniversity of Chicago
Oct 5, 2021
Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome Trial in Atlanta (MLN9708)
Completed
- Acute Leukemia
- +4 more
-
Atlanta, GeorgiaNorthside Hospital
Sep 1, 2021
Multiple Myeloma Trial (Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate)
Approved for marketing
- Multiple Myeloma
- Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate
- (no location specified)
Mar 9, 2021
Multiple Myeloma Trial in Worldwide (Selinexor, Dexamethasone)
Completed
- Multiple Myeloma
-
Birmingham, Alabama
- +60 more
Jan 24, 2023
Advanced Cancers Trial in Guangzhou, Changsha (TQB3602 Capsule + AK105 Injection)
Not yet recruiting
- Advanced Cancers
- TQB3602 Capsule + AK105 Injection
-
Guangzhou, Guangdong, China
- +1 more
Apr 12, 2022
Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory Trial
Not yet recruiting
- Waldenstrom Macroglobulinemia
- +2 more
- (no location specified)
Jul 18, 2023
Quality of Life in Relapsed and/or Refractory Multiple Myeloma
Active, not recruiting
- Multiple Myeloma
-
Morrisville, North CarolinaLocal Institution
May 12, 2022
Real-life Current Standards of Care in Relapsed and/or
Completed
- Multiple Myeloma
- No intervention
-
Tucson, Arizona
- +85 more
Dec 20, 2022